Skip to main content
S 882 111th Congress Senate Health Department of Health and Human Services Drug safety, medical device, and laboratory regulation Employment discrimination and employee rights Executive agency funding and structure Food and Drug Administration (FDA) Government information and archives Government studies and investigations Health technology, devices, supplies Licensing and registrations Prescription drugs Product safety and quality Trade restrictions User charges and fees

Drug and Device Accountability Act of 2009

Introduced: April 23, 2009 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 23, 2009
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Apr 23, 2009
Introduced in Senate
 Plain-English summary Congressional Research Service

Drug and Device Accountability Act of 2009 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to revise provisions regarding the registration of drug and device establishments, including to: (1) expand the information required to be included in a registration; and (2) provide for risk-based inspections.

Includes in the definition of "drug" a precursor ingredient.

Requires the Secretary of Health and Human Services (HHS) to assess the registration exemption for manufacturers of harmless inactive ingredients that become components of drugs.

Deems a drug to be adulterated if certain conditions related to verification of identity and purity, identification of establishments, consistency with current manufacturing technologies, and conformity with good distribution and import practices are not met.

Deems a drug or device to be misbranded unless certain conditions related to labeling for country of manufacture and provision of required information on importation are met.

Sets forth provisions governing importation of a drug and its components.

Sets forth required actions, including cessation of distribution, if there is a reasonable probability that a drug intended for human use would cause serious, adverse health consequences or death.

Establishes actions manufacturers must take regarding any defective drug.

Sets forth additional required certifications for submissions related to drugs and devices regarding accuracy and personal knowledge of information submitted.

Establishes whistleblower protection for employees providing information regarding a drug, biological product, or device.

Requires the Secretary to contract with the Institute of Medicine to evaluate: (1) the organizational structure and operations of the Food and Drug Administration (FDA) with respect to the review of medical devices for clearance and for premarket approval under FFDCA; and (2) the analytical and methodological tools used to conduct such reviews.

Directs the Secretary to establish a corps of inspectors dedicated to inspections of foreign establishments and facilities.

Sets forth enforcement provisions.

What's happening now April 23, 2009

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Republican 1